Manchanda Tarang, Schiedel Dan, Fischer Dan, Dekaban Gregory A, Rieder Michael J
John P Robarts Research Institute, Department of Paediatrics, University of Western Ontario, London.
Can J Clin Pharmacol. 2002 Fall;9(3):137-46.
Protease inhibitors are drugs that are commonly used in the therapy of people living with HIV infection. These drugs are commonly used in combination and act by inhibiting viral protease, blocking viral replication. Adverse drug reactions to protease inhibitors include gastrointestinal problems, rash and metabolic disturbances. The metabolic derangements associated with protease inhibitor therapy are the most problematic adverse events associated with therapy, and vary in incidence from drug to drug. These derangements include hyperlipidemia, abnormal fat distribution (lipodystrophy) and impaired glucose tolerance, which is believed to be due to peripheral insulin resistance. Clinicians caring for patients being treated with protease inhibitors must be vigilant for adverse events, notably those involving altered lipid and glucose metabolism.
蛋白酶抑制剂是常用于治疗人类免疫缺陷病毒（HIV）感染者的药物。这些药物通常联合使用，通过抑制病毒蛋白酶来发挥作用，从而阻断病毒复制。蛋白酶抑制剂的药物不良反应包括胃肠道问题、皮疹和代谢紊乱。与蛋白酶抑制剂治疗相关的代谢紊乱是治疗中最成问题的不良事件，且不同药物的发生率有所不同。这些紊乱包括高脂血症、异常脂肪分布（脂肪营养不良）和糖耐量受损，据信这是由于外周胰岛素抵抗所致。治疗使用蛋白酶抑制剂患者的临床医生必须警惕不良事件，尤其是那些涉及脂质和葡萄糖代谢改变的事件。
